Proparacaine
- Generic Name
- Proparacaine
- Brand Names
- Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H26N2O3
- CAS Number
- 499-67-2
- Unique Ingredient Identifier
- B4OB0JHI1X
- Background
Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.
- Indication
Used as a local (ophthalmic) anesthetic.
- Associated Conditions
- Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Associated Therapies
- Local Anaesthesia therapy
A Study of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy
- First Posted Date
- 2012-03-16
- Last Posted Date
- 2022-01-05
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 89
- Registration Number
- NCT01556776
- Locations
- 🇩🇪
University Hospital Cologne, Cologne, Germany
🇩🇪German CLL Study Group, Cologne, Germany
Nelfinavir and Lenalidomide/Dexamethasone in Progressive Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2012-03-15
- Last Posted Date
- 2022-07-07
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 33
- Registration Number
- NCT01555281
- Locations
- 🇨🇭
Kantonsspital Olten, Olten, Switzerland
🇨🇭UniversitätsSpital Zürich, Zürich, Switzerland
🇮🇹Istituto Europeo di Oncologia IEO, Milano, Italy
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
- Conditions
- Neurofibromatosis Type 1Recurrent Childhood Visual Pathway GliomaRecurrent Childhood Pilocytic Astrocytoma
- Interventions
- Drug: LenalidomideOther: Pharmacological Study
- First Posted Date
- 2012-03-14
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 75
- Registration Number
- NCT01553149
- Locations
- 🇦🇺
Royal Brisbane and Women's Hospital, Herston, Queensland, Australia
🇺🇸Valley Children's Hospital, Madera, California, United States
🇺🇸Lurie Children's Hospital-Chicago, Chicago, Illinois, United States
Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL)
- First Posted Date
- 2012-03-14
- Last Posted Date
- 2021-07-26
- Lead Sponsor
- The Lymphoma Academic Research Organisation
- Target Recruit Count
- 80
- Registration Number
- NCT01553786
- Locations
- 🇧🇪
Universitair Ziekenhuis Gent, Gent, Belgium
🇫🇷CHU Lyon Sud, Pierre Bénite, France
🇫🇷CHU Angers, Angers, France
Lenalidomide as Second-line Treatment for Advanced Hepatocellular Carcinoma
- First Posted Date
- 2012-03-07
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 55
- Registration Number
- NCT01545804
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma
- Conditions
- Recurrent/Refractory CNSIntraocular Lymphoma
- Interventions
- First Posted Date
- 2012-03-02
- Last Posted Date
- 2020-08-11
- Lead Sponsor
- James Rubenstein
- Target Recruit Count
- 14
- Registration Number
- NCT01542918
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2012-02-23
- Last Posted Date
- 2015-01-26
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 7
- Registration Number
- NCT01537861
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)
- Conditions
- Myeloma
- Interventions
- First Posted Date
- 2012-02-13
- Last Posted Date
- 2015-06-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 14
- Registration Number
- NCT01531998
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Lenalidomide and Low Dose Dexamethasone Versus Bortezomib, Lenalidomide and Low Dose Dexamethasone for Induction, in Patients With Previously Untreated Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2012-02-10
- Last Posted Date
- 2016-02-25
- Target Recruit Count
- 440
- Registration Number
- NCT01530594
- Locations
- 🇸🇦
King Faisal Specialist Hospital &Reseach Center, Riyadh, Saudi Arabia
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
- Conditions
- Chronic Myelomonocytic LeukemiaChronic Myelomonocytic Leukemia-1Chronic Myelomonocytic Leukemia-2Myelodysplastic Syndrome With Excess Blasts-1Myelodysplastic SyndromeMyelodysplastic Syndrome With Excess BlastsMyelodysplastic Syndrome/Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2012-02-01
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 282
- Registration Number
- NCT01522976
- Locations
- 🇺🇸
AdventHealth Orlando, Orlando, Florida, United States
🇺🇸Saint Joseph Hospital - Cancer Centers of Colorado, Denver, Colorado, United States
🇺🇸University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.